Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Business Manager
claire@zenopa.com
+44 1494 818025

Testimonials
I have worked with Zenopa both in selecting and obtaining a new role. I have found them to be affable, friendly and well informed.
Tony, 2011

GlaxoSmithKline joins WIPO Re:Search platform for tropical diseases

26 October 2011 00:00 in Pharmaceutical Company Product News


GlaxoSmithKline will help to fight the spread of neglected tropical diseases (NTDs) as part of the WIPO Re:Search platform.

The pharmaceutical giant has joined the project, which is sponsored by the World Intellectual Property Organization (WIPO) in partnership with BIO Ventures for Global Health.

WIPO Re:Search provides a searchable, public database of intellectual property assets and resources to support organisations developing new medicines for diseases such as dengue, rabies, malaria and tuberculosis.

It is estimated that more than one billion people are affected by NTDs each year, with many victims living the world's poorest countries.

"A challenge on this scale requires industry, academia, NGOs and governments to work in partnership to develop new tools and approaches," said Duncan Learmouth, senior vice-president of GlaxoSmithKline's developing countries and market access operating unit.

The company has agreed to contribute its anti-malarial dataset, which includes 13,500 compounds that have shown evidence of activity against malaria in screening, to WIPO Re:Search.

Other companies involved in the project include AstraZeneca, Eisai, Merck, Novartis and Pfizer.ADNFCR-8000103-ID-800776302-ADNFCR

Other news stories from 26/10/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



             
© Copyright 2013 Zenopa Ltd